Synthesis and anticancer properties of celastrol derivatives involved in the inhibition of VEGF

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Marra A, Curigliano G. Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J. 2021;27(1):41–49.
   PubMed Web of Science ®Google Scholar
• Lu M, Zheng J, Xu N, Lin H, Wan S. Postoperative chemotherapy as adjuvant treatment for endometrioid adenocarcinoma: early stage vs late stage. Cancer Chemother Pharmacol. 2019;84(2):299–305.
   PubMed Web of Science ®Google Scholar
• Bray F, Møller B. Predicting the future burden of cancer. Nat Rev Cancer. 2006;6(1):63–74.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Kim R, Kim TW, O’Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, et al. Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice. Clin Colorectal Cancer. 2022;21(4):e117–e129.
   PubMedGoogle Scholar
• Yang L, Wen KS, Ruan X, Zhao YX, We F, Wang Q. Response of plant secondary metabolites to environmental factors. Molecules. 2018; 23(4):762.
   PubMed Web of Science ®Google Scholar
• Monneret C. Impact actuel des produits naturels sur la découverte de nouveaux médicaments anticancéreux [Current impact of natural products in the discovery of anticancer drugs]. Ann Pharm Fr. 2010;68(4):218–232.
   PubMedGoogle Scholar
• Deng LJ, Qi M, Li N, Lei YH, Zhang DM, Chen JX. Natural products and their derivatives: Promising modulators of tumor immunotherapy. J Leukoc Biol. 2020;108(2):493–508.
   PubMed Web of Science ®Google Scholar
• Kubczak M, Szustka A, Rogalińsk M. Molecular targets of natural compounds with anti-cancer properties. Int J Mol Sci. 2021; 22(24):13659.
   PubMed Web of Science ®Google Scholar
• Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011;303(1):9–20.
   PubMed Web of Science ®Google Scholar
• Luo D, Guo Y, Cheng Y, Zhao J, Wang Y, Rong J. Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-κB pathways. Aging. 2017;9(10):2069–2082.
   PubMedGoogle Scholar
• Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009;20(10):880–892.
   PubMed Web of Science ®Google Scholar
• Narayan V, Ravindra KC, Chiaro C, Cary D, Aggarwal BB, Henderson AJ, Prabhu KS. Celastrol inhibits Tat-mediated human immunodeficiency virus (HIV) transcription and replication. J Mol Biol. 2011;410(5):972–983.
   PubMed Web of Science ®Google Scholar
• Peng B, Xu L, Cao F, Wei T, Yang C, Uzan G, Zhang D. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer. 2010;9:79.
   PubMed Web of Science ®Google Scholar
• Salvador JAR, Leal AS, Valdeira AS, Gonçalves BMF, Alho DPS, Figueiredo SAC, Silvestre SM, Mendes VIS. Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment. Eur J Med Chem. 2017;142:95–130.
   PubMed Web of Science ®Google Scholar
• Tang K, Huang Q, Zeng J, Wu G, Huang J, Pan J, Lu W. Design, synthesis and biological evaluation of C6-modified celastrol derivatives as potential antitumor agents. Molecules. 2014;19(7):10177–10188.
   PubMed Web of Science ®Google Scholar
• Han X, Sun S, Zhao M, Cheng X, Chen G, Lin S, Guan Y, Yu X. Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1α protein synthesis. PLOS One. 2014;9(11):e112470.
   PubMed Web of Science ®Google Scholar
• H, Yang H, D, Chen D, QC, Cui X, Yuan QP. Dou Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006;66(9):4758–4765.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang Z, Zhang S, Ren J, Zhang R, Zeng H, Li Q, Wu G. Inhibitory action of Celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1α pathway. Int J Mol Med. 2011;27(3):407–415.
   PubMed Web of Science ®Google Scholar
• Huang S, Tang Y, Cai X, Peng X, Liu X, Zhang L, Xiang Y, Wang D, Wang X, Pan T. Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun. 2012;423(3):467–472.
   PubMed Web of Science ®Google Scholar
• Kang H, Lee M, Jang SW. Celastrol inhibits TGF-β1-induced epithelial-mesenchymal transition by inhibiting Snail and regulating E-cadherin expression. Biochem Biophys Res Commun. 2013;437(4):550–556.
   PubMed Web of Science ®Google Scholar
• Kashyap D, Sharma A, Tuli HS, Sak K, Mukherjee T, Bishayee A. Molecular targets of celastrol in cancer: recent trends and advancements. Crit Rev Oncol Hematol. 2018;128:70–81.
   PubMed Web of Science ®Google Scholar
• Tang WJ, Wang J, Tong X, Shi JB, Liu XH, Li J. Design and synthesis of celastrol derivatives as anticancer agents. Eur J Med Chem. 2015;95:166–173.
   PubMed Web of Science ®Google Scholar
• Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem. 2016;24(21):5431–5439.
   PubMed Web of Science ®Google Scholar
• Hou W, Liu B, Xu H. Celastrol: Progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology. Eur J Med Chem. 2020;189:112081.
   PubMed Web of Science ®Google Scholar
• Bai X, Fu RJ, Zhang S, Yue SJ, Chen YY, Xu DQ, Tang YP. Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases. Biomed Pharmacother. 2021;139:111551.
   PubMed Web of Science ®Google Scholar
• Han Y, Dong W, Guo Q, Li X, Huang L. The importance of indole and azaindole scaffold in the development of antitumor agents. Eur J Med Chem. 2020;203:112506.
   PubMed Web of Science ®Google Scholar
• Wan Y, Li Y, Yan C, Yan, Tang MZ. Indole: a privileged scaffold for the design of anti-cancer agents. Eur J Med Chem. 2019;183:111691.
   PubMed Web of Science ®Google Scholar
• Tian DL, Liang CP, Liang J, Chen H. Synthesis and antitumor activity of novel indole podophyllotoxin derivatives. Zhongguo Zhong Yao Za Zhi. 2019;44(12):2532–2537.
   PubMedGoogle Scholar
• Sang YL, Zhang WM, Lv PC, Zhu HL. Indole-based, antiproliferative agents targeting tubulin polymerization. Curr Top Med Chem. 2017;17(2):120–137.
   PubMedGoogle Scholar
• Han L, Li T, Miao D, Lee J, Xiao S, Piao H, Zhao Y. Design, synthesis and cytotoxicity evaluation of novel indole derivatives of panaxadiol. Chem Biodivers. 2022;19(8):e202200372.
   PubMed Web of Science ®Google Scholar
• Berlinck RGS, Crnkovic CM, Gubiani JR, Bernardi DI, Ióca LP, Quintana-Bulla JL. The isolation of water-soluble natural products – challenges, strategies and perspectives. Nat Prod Rep. 2022;39(3):596–669.
   PubMed Web of Science ®Google Scholar
• Joshi G, Singh PK, Negi A, Rana A, Singh S, Kumar R. Growth factors mediated cell signalling in prostate cancer progression: implications in discovery of anti-prostate cancer agents. Chem Biol Interact. 2015;240:120–133.
   PubMed Web of Science ®Google Scholar
• Qi S, Deng S, Lian Z, Yu K. Novel drugs with high efficacy against tumor angiogenesis. Int J Mol Sci. 2022;23:6934.
   PubMedGoogle Scholar
• Song Z, Wang J, Su Q, Luan M, Chen X, Xu X. The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. Braz J Otorhinolaryngol. 2021;87(5):521–528.
   PubMed Web of Science ®Google Scholar
• Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4(4):314–320.
   PubMed Web of Science ®Google Scholar
• Roșu MC, Mihnea PD, Ardelean A, Moldovan SD, Popețiu RO, Totolici BD. Clinical significance of tumor necrosis factor-alpha and carcinoembryonic antigen in gastric cancer. J Med Life. 2022;15(1):4–6.
   PubMedGoogle Scholar
• Zhao K, Jiang Y, Zhang J, Shi J, Zheng P, Yang C, Chen Y. Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway. Cell Cycle. 2022;21(19):2091–2108.
   PubMed Web of Science ®Google Scholar
• Ma J, Li J, Tian YS. Synthesis and bioactivity evaluation of 2,3-diaryl acrylonitrile derivatives as potential anticancer agents. Bioorg Med Chem Lett. 2017;27(1):81–85.
   PubMed Web of Science ®Google Scholar
• Zhang HJ, Zhang GR, Piao HR, Quan ZS. Synthesis and characterisation of celastrol derivatives as potential anticancer agents. J Enzyme Inhib Med Chem. 2017;33(1):190–198.
   PubMed Web of Science ®Google Scholar
• Rosen R, Vagaggini T, Chen Y, Hu DN. Zeaxanthin inhibits hypoxia-induced VEGF secretion by RPE cells through decreased protein levels of hypoxia-inducible factors-1α. Biomed Res Int. 2015;2015:687386.
   PubMed Web of Science ®Google Scholar
• Ward MP, Spiers JP. Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion. Br J Pharmacol. 2017;174(10):1116–1130.
   PubMed Web of Science ®Google Scholar
• Wang G, Xiao Q, Wu Y, Wei YJ, Jing Y, Cao XR, Gong ZN. Design and synthesis of novel celastrol derivative and its antitumor activity in hepatoma cells and antiangiogenic activity in zebrafish. J Cell Physiol. 2019;234(9):16431–16446.
   PubMed Web of Science ®Google Scholar